NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Nice try Bluesky.

1. We have the individual differences between the patients for cancer type, how long the survive, and for those who passed, what method treatment they were given. Moreover, we know the group patient characteristics, including the median number of prior treatments, the stage (IV) of cancer and that their cancers were inoperable.

2. Diagnosed rate of progression is not given, and would not typically be given in a stage I trial until final results are published (if then), but we currently know:

All patients had stage 4, locally advanced or metastatic disease
• Patients had an average of 3 tumor lesions
• Patients had a median of 3.1 prior therapies

Consider, stage IV patients that had already failed 3 prior therapies on average. Bluesky, please come back to me with a phase I trial showing diagnosed rate of progression prior to experimental treatment.

3. We do not know phase I inclusion criteria for minimal survival prognosis was changed during the phase I enrollment. Your hypothesis is that they changed it during phase I enrollment.

4. I gave you the mix of A and B, you are welcome. And even if you took the extreme case, and placed all method B survivors in the lower group of 9-14 months, and method A survivors from 14 to 17 months, they are all still alive! Even under an extreme division like that, both groups would still be doing phenomenally.